All News

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.

Polygenic risk score was found to be associated with a higher risk of primary open angle glaucoma (POAG) in patients with ocular hypertension.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.

These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).

For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.

Older adults with advanced breast cancer need personalized treatment plans considering fitness, preferences, and potential limitations for optimal outcomes and quality of life.

Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans for patients.

The Duchenne muscular dystrophy (DMD) treatment vamorolone received FDA approval in October 2023 and is a less toxic alternative to conventional corticosteroids.

The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

The approval makes atidarsagene autotemcel (arsa-cel [Lenmeldy]; Orchard Therapeutics) the first approved treatment for metachromatic leukodystrophy, a disease caused by a mutation in the ARSA gene and marked by progressive declines in both the central and peripheral nervous systems.

Posters presented at the American Academy of Dermatology 2024 Annual Meeting identified significant health disparities among patients living in rural areas and those with skin of color (SOC).

Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).

A review found that global retinal sensitivity changes in mesopic and scotopic lighting were significant in age-related macular degeneration (AMD).

A study weighed the different comorbidities associated with asthma among a study population based in Finland.

Posters reported the prevalence of autoimmune comorbidities among patients with vitiligo, demonstrating the need for earlier screenings and updated clinical guidelines.

Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.

UnitedHealth Group aims to restore services amid investigations; providers advised to administer measles vaccine to infants before international travel; study finds significant increase in medication abortions after Supreme Court decision.

Posters presented showed that patients with vitiligo have a heightened risk of stigma and subsequent mental health issues.

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.

Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.

Two strategies were tried, but neither outperformed usual care.

AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.

Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.

This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.

This secondary analysis follows initial results from a phase 3 trial, which suggested that vitamin D supplementation with ergocalciferol improved insulin sensitivity, subsequently slowing the rise of insulin requirements in patients who have type 1 diabetes (T1D).

The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.

A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.